Actinium Pharmaceuticals (NYSE:ATNM - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 210.08% from the stock's previous close. HC Wainwright also issued estimates for Actinium Pharmaceuticals' Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($1.08) EPS.
Actinium Pharmaceuticals Stock Performance
Actinium Pharmaceuticals stock traded down $0.10 during trading on Tuesday, reaching $1.29. The company had a trading volume of 304,206 shares, compared to its average volume of 499,350. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24. The stock's 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.44. The firm has a market capitalization of $40.24 million, a price-to-earnings ratio of -0.93 and a beta of -0.27.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Squarepoint Ops LLC raised its holdings in shares of Actinium Pharmaceuticals by 25.4% in the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company's stock worth $231,000 after purchasing an additional 37,159 shares during the period. Nuveen Asset Management LLC increased its position in shares of Actinium Pharmaceuticals by 49.5% in the fourth quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company's stock worth $187,000 after acquiring an additional 49,214 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company's stock valued at $155,000 after acquiring an additional 99,158 shares during the period. Bank of America Corp DE lifted its holdings in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company's stock valued at $99,000 after acquiring an additional 34,176 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company's stock valued at $317,000 after acquiring an additional 11,812 shares in the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.
About Actinium Pharmaceuticals
(
Get Free Report)
Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
See Also
Before you consider Actinium Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actinium Pharmaceuticals wasn't on the list.
While Actinium Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
